Clinical trial · Observational
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma
Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma
NCT01490801CI-TRIAL-00022221completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with Epstein-Barr virus positive Hodgkin lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Nonneoplastic Condition | — | UNRESOLVED | — |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytogenetic analysis | Genetic | — | UNRESOLVED |
| DNA analysis | Genetic | — | UNRESOLVED |
| flow cytometry | Other | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| in situ hybridization | Genetic | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — | UNRESOLVED |
| RNA analysis | Genetic |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Presence of germline ITK mutations
- measure
- Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein
- measure
- Correlation between ITK mutations with specific clinical or histopathological features of HL
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 9 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of Hodgkin lymphoma (HL) meeting the following criteria: * Epstein-Barr virus-positive (EBV+) HL as assessed by positive EBV serology, elevated levels of EBV genome in the blood or tumor tissue following quantitative polymerase chain reaction (PCR) and/or evidence of EBV positivity of pathology samples (EBER+ or LMP+) and, when possible, mixed cellular histology * Young age (\< 10 years) at diagnosis * Presence of hemophagocytic lymphohistiocytosis (HLH) PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.